Exact Sciences Corporation

NasdaqCM:EXAS Stock Report

Market Cap: US$10.3b

Exact Sciences Valuation

Is EXAS undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

6/6

Valuation Score 6/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of EXAS when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Discounted Cash Flow
Simply Wall St
US$176.87
Fair Value
69.0% undervalued intrinsic discount
23
Number of Analysts

Below Fair Value: EXAS ($54.89) is trading below our estimate of fair value ($176.87)

Significantly Below Fair Value: EXAS is trading below fair value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for EXAS?

Key metric: As EXAS is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for EXAS. This is calculated by dividing EXAS's market cap by their current revenue.
What is EXAS's PS Ratio?
PS Ratio3.8x
SalesUS$2.69b
Market CapUS$10.26b

Price to Sales Ratio vs Peers

How does EXAS's PS Ratio compare to its peers?

The above table shows the PS ratio for EXAS vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PSEstimated GrowthMarket Cap
Peer Average4.8x
EXEL Exelixis
4.5x9.3%US$9.3b
BMRN BioMarin Pharmaceutical
4.4x7.4%US$12.1b
SRPT Sarepta Therapeutics
6.7x17.8%US$11.2b
INCY Incyte
3.5x5.4%US$14.1b
EXAS Exact Sciences
3.8x9.3%US$10.3b

Price-To-Sales vs Peers: EXAS is good value based on its Price-To-Sales Ratio (3.8x) compared to the peer average (4.8x).

Price to Sales Ratio vs Industry

How does EXAS's PS Ratio compare vs other companies in the US Biotechs Industry?

138 CompaniesPrice / SalesEstimated GrowthMarket Cap
Industry Avg.10.1x18.3%
EXAS Exact Sciences
 3.8x9.3%US$10.26b
BIIB Biogen
2.2x1.2%US$21.20b
MRNA Moderna
3.1x10.9%US$17.29b
EXAS 3.8xIndustry Avg. 10.1xNo. of Companies138PS01632486480+
138 CompaniesEstimated GrowthMarket Cap
Industry Avg.10.1x27.3%
EXAS Exact Sciences
 3.8x59.1%US$10.26b
No more companies

Price-To-Sales vs Industry: EXAS is good value based on its Price-To-Sales Ratio (3.8x) compared to the US Biotechs industry average (10.1x).

Price to Sales Ratio vs Fair Ratio

What is EXAS's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

EXAS PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio3.8x
Fair PS Ratio5.8x

Price-To-Sales vs Fair Ratio: EXAS is good value based on its Price-To-Sales Ratio (3.8x) compared to the estimated Fair Price-To-Sales Ratio (5.8x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst EXAS forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentUS$54.89
US$72.19
+31.5%
10.3%US$95.00US$61.00n/a23
Jan ’26US$56.19
US$71.86
+27.9%
11.5%US$95.00US$60.00n/a21
Dec ’25US$62.08
US$70.81
+14.1%
9.1%US$86.00US$60.00n/a21
Nov ’25US$69.80
US$80.33
+15.1%
11.4%US$100.00US$61.00n/a21
Oct ’25US$68.04
US$78.19
+14.9%
10.2%US$100.00US$61.00n/a21
Sep ’25US$61.69
US$75.81
+22.9%
11.5%US$100.00US$60.00n/a21
Aug ’25US$57.91
US$76.10
+31.4%
11.8%US$100.00US$60.00n/a20
Jul ’25US$42.43
US$80.96
+90.8%
12.2%US$100.00US$60.00n/a21
Jun ’25US$45.45
US$85.36
+87.8%
9.6%US$100.00US$66.00n/a20
May ’25US$60.01
US$89.37
+48.9%
11.3%US$115.00US$66.00n/a20
Apr ’25US$70.41
US$88.49
+25.7%
10.9%US$115.00US$66.00n/a21
Mar ’25US$59.44
US$88.49
+48.9%
10.9%US$115.00US$66.00n/a21
Feb ’25US$63.93
US$89.45
+39.9%
11.7%US$115.00US$66.00n/a21
Jan ’25US$73.98
US$89.23
+20.6%
12.9%US$115.00US$66.00US$56.1919
Dec ’24US$67.03
US$90.02
+34.3%
15.4%US$120.00US$66.00US$62.0817
Nov ’24US$63.52
US$104.64
+64.7%
16.1%US$130.00US$78.00US$69.8017
Oct ’24US$68.22
US$107.46
+57.5%
14.6%US$130.00US$68.00US$68.0417
Sep ’24US$85.16
US$107.88
+26.7%
14.0%US$130.00US$68.00US$61.6917
Aug ’24US$96.44
US$101.40
+5.1%
16.9%US$130.00US$64.00US$57.9118
Jul ’24US$93.90
US$99.68
+6.2%
17.6%US$130.00US$64.00US$42.4318
Jun ’24US$83.84
US$84.79
+1.1%
11.2%US$100.00US$64.00US$45.4518
May ’24US$63.41
US$75.37
+18.9%
11.2%US$92.00US$55.00US$60.0117
Apr ’24US$67.81
US$74.41
+9.7%
13.0%US$92.00US$55.00US$70.4117
Mar ’24US$62.45
US$70.24
+12.5%
15.6%US$92.00US$50.00US$59.4417
Feb ’24US$68.11
US$63.76
-6.4%
22.6%US$89.00US$35.00US$63.9317
Jan ’24US$49.51
US$58.06
+17.3%
18.6%US$75.00US$35.00US$73.9818
Analyst Price Target
Consensus Narrative from 23 Analysts
US$72.19
Fair Value
24.0% undervalued intrinsic discount
23
Number of Analysts

Analyst Forecast: Target price is more than 20% higher than the current share price and analysts are within a statistically confident range of agreement.

Discover undervalued companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/01/29 05:40
End of Day Share Price 2025/01/29 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Exact Sciences Corporation is covered by 47 analysts. 24 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Catherine Ramsey SchulteBaird
Luke SergottBarclays
Bruce JacksonBenchmark Company